Tag Archives: American Association for the Study of Liver Diseases Conference

HCV / HIV Co-Infection Topics Presented at #EASLsp

HCV / HIV Co-Infection Topics Presented at #EASLspThe European Association for the Study of the Liver (EASL) / American Association for the Study of Liver Diseases (AASLD)’s two day special conference, entitled “New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure” (#EASLsp), was held last week in Paris, France. The conference has gathered experts to review and analysis current hepatitis C (HCV) treatment data, published and unpublished. This blog covers just some of what was presented about HCV/HIV co-infection.

Some HCV / HIV Co-Infection Topics Presented in Paris

The links below may need to be clicked twice or waited for in order to work.

Summary: Due to the complex way liver disease develops, the higher risk of hep C and re-infection, and the risk for drug interactions with antiretrovirals, frequently not addressed in clinical trials, those with HCV/HIV co-infection still pose challenges.

Summary: HCV/HIV co-infection is prevalent in those who use opiates. However, little is known about the results of opiate replacement treatment (ORT) for those with hep C and those who are HCV/HIV co-infected who are in ORT. This study saw that HCV/HIV co-infected patients received more methadone when compared with patients without infections. No differences in methadone doses were found in those with hep C. It also showed that hep C doesn’t cause any difference in whether or not the opiate replacement treatment (ORT) will work long term.

Summary: This study looked at the effectiveness of direct-acting antivirals (DAAs), a type of hep C treatment, in real life. It looked at interactions between HCV/HIV treatments and monitored liver fibrosis, transaminases, and alpha-fetoprotein (AFP) changes while taking treatment. The study found that direct-acting antivirals (DAAs) are effective and improve liver fibrosis, hepatic cytolysis, and AFP.

For more information about studies presented at the EASL / AASLD special conference in Paris last week, please find Part I of the conference’s blog series here and Part II here.